Cognito Therapeutics raises $73M Series B for Alzheimer's neuromodulation platform
Summary
Cognito Therapeutics raised $73 million in Series B financing led by FoundersX Ventures, with participation from all existing investors and new investors including the Alzheimer's Drug Discovery Foundation, Starbloom Capital, IAG Capital, and WS Investment Company. The Cambridge-based neurotechnology company is advancing a non-invasive neuromodulation device that delivers gamma frequency light and sound stimulation for Alzheimer's disease treatment.
Why it matters
The Series B brought Cognito's total funding to $93 million and enabled the launch of the HOPE pivotal study across approximately 50 clinical centers in the United States targeting 500 patients. With prior Phase 2 data showing significant slowing of functional and cognitive decline plus reduction in brain atrophy, the financing represented a critical inflection point in bringing drug-free neuromodulation to the Alzheimer's treatment landscape.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial